Stoke Therapeutics, Inc. - Common Stock (STOK)
6.6000
+0.3700 (5.94%)
NASDAQ · Last Trade: Apr 2nd, 6:46 PM EDT
Via Benzinga · March 18, 2025

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.
Via Benzinga · February 18, 2025

Via Benzinga · February 11, 2025

Via Benzinga · January 8, 2025

Via Benzinga · December 4, 2024

Via Benzinga · June 28, 2024

Via Benzinga · June 24, 2024

STOK stock results show that Stoke Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 6, 2024

Via Benzinga · April 5, 2024

Via Benzinga · April 4, 2024

Via Benzinga · April 4, 2024

Via Benzinga · March 27, 2024

After the market close on Tuesday, Stoke Therapeutics announced a proposed underwritten public offering of up to $75 million of its common stock. The company also intends to grant the underwriters a 30-day window to purchase up to an additional 15% of the shares in the public offering.
Via Benzinga · March 26, 2024

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 80 points on Tuesday. The Dow traded up 0.21% to 39,397.20 while the NASDAQ rose 0.23% to 16,421.62. The S&P 500 also rose, gaining, 0.17% to 5,227.03.
Via Benzinga · March 26, 2024

Via Benzinga · March 26, 2024

U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 100 points on Tuesday. The Dow traded up 0.25% to 39,413.30 while the NASDAQ rose 0.27% to 16,448.55. The S&P 500 also rose, gaining, 0.27% to 5,232.36.
Via Benzinga · March 26, 2024

Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81 cents per share, compared to market expectations for a loss of 51 cents per share.
Via Benzinga · March 26, 2024

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 50 points on Tuesday. The Dow traded up 0.08% to 39,346.40 while the NASDAQ rose 0.39% to 16,448.92. The S&P 500 also fell, dropping, 0.23% to 5,230.19.
Via Benzinga · March 26, 2024

New data from Stoke Therapeutics' STK-001 studies reveal significant reductions in seizures and cognitive improvements in children with Dravet syndrome. STK-001 demonstrates promise as a well-tolerated treatment option, even for highly refractory patients.
Via Benzinga · March 26, 2024

NeuBase Therapeutics stock is down on Tuesday as NBSE investors react to details concerning an upcoming special shareholder meeting.
Via InvestorPlace · March 26, 2024

Via Benzinga · March 26, 2024

Check-Cap stock is up on Tuesday with heavy trading as CHEK investors react to news of a business combination with Nobul AI.
Via InvestorPlace · March 26, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via Benzinga · March 26, 2024

Shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) rose sharply in today’s pre-market trading after the company announced Phase 1/2a data supporting the potential for STK-001
Via Benzinga · March 26, 2024